FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT
THIS FIRST AMENDMENT TO COMMON STOCK PURCHASE AGREEMENT (the "Amendment"),
dated as of April 19, 2006, by and between HEMISPHERX BIOPHARMA, INC., a
Delaware corporation (the "Company"), and FUSION CAPITAL FUND II, LLC, an
Illinois limited liability company (the "Buyer"). Capitalized terms used herein
and not otherwise defined herein shall have the meanings given to them in the
Common Stock Purchase Agreement.
WHEREAS, the parties hereto are parties to a Common Stock Purchase
Agreement dated as of April 12, 2006 (the "Common Stock Purchase Agreement")
pursuant to which the Buyer has agreed to purchase, and the Company has agreed
to sell up to $50,000,000 of the Common Stock;
WHEREAS, the parties desire to amend the Common Stock Purchase Agreement;
NOW, THEREFORE, in consideration of the agreements, covenants and
considerations contained herein, the parties hereto agree as follows:
1. Amendments. Section 1(g) is hereby amended and restated in its
entirety as follows:
(g) Compliance with Principal Market Rules. The Company shall
not effect any sale under this Agreement and the Buyer shall not
have the right or the obligation to purchase shares of Common Stock
under this Agreement to the extent that after giving effect to such
purchase the "Exchange Cap" shall be deemed to be reached. The
"Exchange Cap" shall be deemed to have been reached if, at any time
prior to the shareholders of the Company approving the transaction
contemplated by this Agreement, upon a purchase under this
Agreement, the Purchase Shares and Commitment Shares issuable
pursuant to such purchase would, together with all Purchase Shares
and Commitment Shares previously issued under this Agreement, exceed
12,386,723 shares of Common Stock (19.99% of the 61,964,598
outstanding shares of Common Stock as of the date of this
Agreement). The Company may, but shall be under no obligation to,
request its shareholders to approve the transaction contemplated by
this Agreement. The Company shall not be required to issue any
shares of Common Stock under this Agreement if such issuance would
breach the Company's obligations under the rules or regulations of
the Principal Market.
2 Effect of Amendment/Incorporation of Certain Provisions. Except as
amended as set forth above, the Common Stock Purchase Agreement
shall continue in full force and affect. The provisions set forth in
Section 11 of the Common Stock Purchase Agreement are hereby
expressly incorporated by reference into this Amendment.
* * * * *
IN WITNESS WHEREOF, the Buyer and the Company have caused this First Amendment
to Common Stock Purchase Agreement to be duly executed as of the date first
written above.
THE COMPANY:
HEMISPHERX BIOPHARMA, INC.
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Name:
Title: CFO
BUYER:
FUSION CAPITAL FUND II, LLC
BY: FUSION CAPITAL PARTNERS, LLC
BY: SGM HOLDINGS CORP.
BY: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: President
2